Congress Scientific Watch

From ESMO Congress 2022:
Patients without evidence of disease after stage IV melanoma surgery or radiotherapy have significantly better overall survival with adjuvant use of nivolumab plus ipilimumab versus placebo

From ESMO Congress 2022:
The PEARLS/KEYNOTE-091 trial points to a disease-free survival advantage with use of adjuvant pembrolizumab after complete resection of stage IB–IIIA NSCLC irrespective of PD-L1 expression

From ESMO Congress 2022:
A study of patients with urachal cancer suggests that the median overall survival duration from this rare tumour type may be longer than previously reported

From ESMO Congress 2022:
Around half of patients with resectable cutaneous squamous cell carcinoma achieved a pathological complete response after 12 weeks of neoadjuvant cemiplimab

From ESMO Congress 2022:
Patients with stage IIIB or IV Merkel cell carcinoma may benefit from nivolumab plus ipilimumab, especially those naïve to immune checkpoint inhibitor therapy

From ESMO Congress 2022:
The KRYSTAL-1 and CodeBreaK 101 studies suggest that metastatic colorectal cancer with a KRAS G12C mutation can be treated with dual targeted therapies

From ESMO Congress 2022:
Patients with EGFR-mutated NSCLC and acquired resistance to first-line osimertinib respond well when later given the tyrosine kinase inhibitor in combination with tepotinib

From ESMO Congress 2022:
Giving streptozotocin–fluorouracil before everolimus may maximise the objective response rate for patients with advanced pancreatic neuroendocrine tumours

From ESMO Congress 2022:
More than half of patients with previously treated HER2-mutant non-small-cell lung cancer responded to treatment with trastuzumab deruxtecan 5.4 mg/kg

From ESMO Congress 2022:
Nivolumab plus ipilimumab after nephrectomy does not extend disease-free survival for high-risk patients with renal cell carcinoma

From ESMO Congress 2022:
Use of enzalutamide alongside abiraterone plus steroids and androgen deprivation therapy does not further improve overall survival of metastatic hormone-sensitive prostate cancer

From ESMO Congress 2022:
Camrelizumab plus rivoceranib may significantly extend survival compared with sorafenib for patients with previously untreated unresectable or metastatic hepatocellular carcinoma